Black Diamond Therapeutics Inc
NASDAQ:BDTX
Intrinsic Value
Black Diamond Therapeutics, Inc. is a precision oncology medicine company, which engages in discovery and development of small molecule, masterkey therapies. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of BDTX.
Black Diamond Therapeutics Inc's market capitalization is 263.9m USD.
BDTX stock price is 5.11 USD.
BDTX.
BDTX. Open DCF Valuation
BDTX. Open Relative Valuation
BDTX has upside potential of 155% compared to the average analyst price target.
Open Wall St Estimates
BDTX has negative Free Cash Flow for the last twelve months.
BDTX has negative Operating Income for the last twelve months.
BDTX has negative Net Income for the last twelve months.
BDTX's ROE (Return on Equity) has significantly decreased in the last 3 years from -27% to -71%, and is approaching profitability.
BDTX's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -857% to -306%, and is approaching profitability.
BDTX's ROE (Return on Equity) for the past 12 months is negative and is equal to -71%.
BDTX's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -306%.
BDTX's long-term assets (159m USD) exceed its long-term liabilties (42m USD).
BDTX has negative three-year average ROE (Return on Equity): -52%. The company is not efficient at transforming stockholders' equity into net income.
BDTX has negative three-year average ROIC (Return on Invested Capital): -436%. The company is not efficient at using invested capital to generate operating income.
BDTX's short-term assets (134m USD) exceed its short-term liabilties (20m USD).
BDTX's D/E (Debt to Equity) is very low and is equal to 0.
BDTX's Altman Z-Score is very low and is equal to -3.53.
Fundamental Analysis
Black Diamond Therapeutics Inc
Balance Sheet Decomposition
Black Diamond Therapeutics Inc
| Current Assets | 134m |
| Cash & Short-Term Investments | 131.4m |
| Other Current Assets | 2.6m |
| Non-Current Assets | 24.5m |
| PP&E | 23.7m |
| Other Non-Current Assets | 823k |
| Current Liabilities | 19.6m |
| Accounts Payable | 2.3m |
| Accrued Liabilities | 17.3m |
| Non-Current Liabilities | 22.2m |
| Other Non-Current Liabilities | 22.2m |
Earnings Waterfall
Black Diamond Therapeutics Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-86.5m
USD
|
|
Operating Income
|
-86.5m
USD
|
|
Other Expenses
|
4m
USD
|
|
Net Income
|
-82.4m
USD
|
Free Cash Flow Analysis
Black Diamond Therapeutics Inc
BDTX Profitability Score
Profitability Due Diligence
Black Diamond Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Black Diamond Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
BDTX Solvency Score
Solvency Due Diligence
Black Diamond Therapeutics Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Score
Black Diamond Therapeutics Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BDTX Price Targets Summary
Black Diamond Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
BDTX
is 13.06 USD
with a low forecast of 10.1 USD and a high forecast of 16.8 USD.
Ownership
BDTX Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
BDTX Price
Black Diamond Therapeutics Inc
| Average Annual Return | -56.04% |
| Standard Deviation of Annual Returns | 33.57% |
| Max Drawdown | -97% |
| Market Capitalization | 263.9m USD |
| Shares Outstanding | 51 720 000 |
| Percentage of Shares Shorted | 6.29% |
Company Profile
Black Diamond Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Black Diamond Therapeutics, Inc. is a precision oncology medicine company, which engages in discovery and development of small molecule, masterkey therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 88 full-time employees. The company went IPO on 2020-01-30. The firm is focused on the discovery and development of small molecule, MasterKey therapies. The Company’s technology platform, Mutation-Allostery-Pharmacology (MAP) platform, is designed to allow it to analyze population-level genetic sequencing data to discover oncogenic mutations that promote cancer across tumor types. Its lead product candidate, BDTX-189, is designed as an orally available, irreversible small molecule inhibitor that targets a spectrum of 48 non-canonical and canonical driver mutations of the ErbB kinases epidermal growth factor receptor (EGFR) and HER2. BDTX-1535 is designed as a brain-penetrant small molecule inhibitor that targets a spectrum of EGFR mutations, including allosteric and canonical mutations. The company also has early-stage programs, such as B-Raf Proto-Oncogene (BRAF), and fibroblast growth factor receptor (FGFR).
You don't have any saved screeners yet
